Brief: Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

Geneuro SA

18/04/2017 06:31

April 18 (Reuters) - Geneuro SA  GNRO.PA : 
    * Geneuro initiates Phase 2a study with GNbAC1 in type 1 
diabetes in Australia 
    * Type 1 diabetes is second GNbAC1's indication after 
multiple sclerosis 
    * Placebo controlled randomized phase 2a study evaluates 
drug candidate targeting potential causal factor in 60 recently 
diagnosed adults 
    * Results expected by Q3 2018 
    * Placebo-Controlled, randomized phase 2a study will 
evaluate GNbAC1 in 60 recently diagnosed adults at over 10 
centers in Australia 
    * Primary endpoint will be safety in this new patient 
population 
 
Source text for Eikon:  ID:nBw11VJ7Xa  
Further company coverage:  GNRO.PA  
 
 (Gdynia Newsroom:) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))